Hepion Approves 1-for-20 to 1-for-50 Reverse Split and 6x Increase in Authorized Shares
CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).
Summary
Hepion Pharmaceuticals' majority stockholders approved a reverse stock split (1-for-20 to 1-for-50) and a sixfold increase in authorized shares to 750 million, positioning the company for further capital raises amid a going concern warning.
Key Events · Corporate Governance and Compliance · CTRVP
-
Reverse Stock Split Approved
Majority stockholders approved a reverse split at a ratio between 1-for-20 and 1-for-50, with the Board holding discretion on the exact ratio and timing. The split must be effected within one year of the August 31, 2026 record date.
-
Authorized Shares Increased 6x
Authorized common shares increased from 120,000,000 to 750,000,000. The filing states the company has no shares available for future issuance, with 98,220,317 shares outstanding and approximately 78.9 million shares reserved for future issuance.
-
Equity Incentive Plan Expanded
The 2023 Omnibus Equity Incentive Plan share pool increased from 8,000,000 to 18,000,000 shares, representing approximately 18.3% of basic outstanding shares and 10.2% on a fully-diluted basis.
-
Going Concern Context
The filing follows the August 10-Q going concern warning and recent private placements at $0.05 per share. The authorized share increase and reverse split are preparatory steps for additional dilutive financings.
Analysis · CTRVP · Life Sciences
Majority stockholders of Hepion Pharmaceuticals have approved a reverse stock split at a ratio between 1-for-20 and 1-for-50, along with a sixfold increase in authorized common shares from 120 million to 750 million. The company currently trades at $0.0013 per share with a market cap of roughly $5 million, and the filing states it has no shares available for future issuance. The reverse split is designed to lift the share price above penny-stock thresholds and reduce manipulation risk, while the authorized share increase gives the board flexibility to raise capital. Given the going concern warning in the August 10-Q and the recent string of deeply discounted private placements, this filing signals the company is preparing for substantial additional dilution to fund operations.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1805 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.